Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Australia, Canada, Hong Kong, and China. For more information, visit www.deciphera.com.
Location: United States, Massachusetts, Waltham
Member count: 201-500
Phone: +1 781-209-6400
Total raised: $127M
Founded date: 2003
Investors 2
Date | Name | Website |
- | SV Health ... | svhealthin... |
- | New Leaf V... | nlvpartner... |
Funding Rounds 2
Date | Series | Amount | Investors | Deal News |
01.06.2017 | Series C | $52M | - | finsmes.co... |
21.09.2015 | Series B | $75M | - | medcitynew... |
Mentions in press and media 24
Date | Title | Description | Category | Author | Source |
17.09.2021 | Deciphera ... | Deciphera Announces Positive C... | - | - | marketscre... |
23.11.2020 | The Boston... | WALTHAM, Mass.--(BUSINESS WIRE... | - | - | svhealthin... |
22.06.2020 | Deciphera ... | June 22, 2020 at 7:00 AM EDTPD... | - | - | svhealthin... |
08.06.2020 | Deciphera ... | June 8, 2020 at 7:30 AM EDTPDF... | - | - | svhealthin... |
29.05.2020 | Deciphera ... | Patients Receiving QINLOCK for... | - | - | svhealthin... |
16.12.2019 | Deciphera ... | – Application is Being Reviewe... | - | - | svhealthin... |
28.10.2019 | FDA to spl... | Shares of Blueprint were down ... | - | - | medcitynew... |
28.09.2017 | Term Sheet... | DIAL UP THE DRAMA Good mornin... | - | - | fortune.co... |
19.09.2017 | Term Sheet... | VCs VERSUS ICOs Companies hav... | - | - | fortune.co... |
05.09.2017 | Term Sheet... | CATCH UP Good morning, Term S... | - | - | fortune.co... |
Show more